CORD-19:954e351a7d8b5d4c275b9af0b053ce983d334547 / 429570-429898 JSONTXT

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T224","span":{"begin":0,"end":328},"obj":"Sentence"}],"text":"In humans, this drug was marketed for women with constipation-predominant or mixed symptom irritable bowel syndrome and demonstrated clear benefits in quality of life and gastrointestinal symptoms but is currently only available in a restricted fashion because of an association with ischemic colitis and cardiovascular disease."}

{"project":"CORD-19-Sentences","denotations":[{"id":"T11461","span":{"begin":0,"end":328},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In humans, this drug was marketed for women with constipation-predominant or mixed symptom irritable bowel syndrome and demonstrated clear benefits in quality of life and gastrointestinal symptoms but is currently only available in a restricted fashion because of an association with ischemic colitis and cardiovascular disease."}

{"project":"Epistemic_Statements","denotations":[{"id":"T1330","span":{"begin":0,"end":328},"obj":"Epistemic_statement"}],"text":"In humans, this drug was marketed for women with constipation-predominant or mixed symptom irritable bowel syndrome and demonstrated clear benefits in quality of life and gastrointestinal symptoms but is currently only available in a restricted fashion because of an association with ischemic colitis and cardiovascular disease."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1696","span":{"begin":21,"end":24},"obj":"Disease"},{"id":"T1697","span":{"begin":49,"end":61},"obj":"Disease"},{"id":"T1698","span":{"begin":91,"end":115},"obj":"Disease"},{"id":"T1699","span":{"begin":284,"end":300},"obj":"Disease"},{"id":"T1700","span":{"begin":293,"end":300},"obj":"Disease"},{"id":"T1701","span":{"begin":305,"end":327},"obj":"Disease"}],"attributes":[{"id":"A1696","pred":"mondo_id","subj":"T1696","obj":"http://purl.obolibrary.org/obo/MONDO_0010518"},{"id":"A1697","pred":"mondo_id","subj":"T1697","obj":"http://purl.obolibrary.org/obo/MONDO_0002203"},{"id":"A1698","pred":"mondo_id","subj":"T1698","obj":"http://purl.obolibrary.org/obo/MONDO_0005052"},{"id":"A1699","pred":"mondo_id","subj":"T1699","obj":"http://purl.obolibrary.org/obo/MONDO_0000701"},{"id":"A1700","pred":"mondo_id","subj":"T1700","obj":"http://purl.obolibrary.org/obo/MONDO_0005292"},{"id":"A1701","pred":"mondo_id","subj":"T1701","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"}],"text":"In humans, this drug was marketed for women with constipation-predominant or mixed symptom irritable bowel syndrome and demonstrated clear benefits in quality of life and gastrointestinal symptoms but is currently only available in a restricted fashion because of an association with ischemic colitis and cardiovascular disease."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T1275","span":{"begin":49,"end":61},"obj":"Phenotype"},{"id":"T1276","span":{"begin":91,"end":100},"obj":"Phenotype"},{"id":"T1277","span":{"begin":293,"end":300},"obj":"Phenotype"},{"id":"T1278","span":{"begin":305,"end":327},"obj":"Phenotype"}],"attributes":[{"id":"A1275","pred":"hp_id","subj":"T1275","obj":"http://purl.obolibrary.org/obo/HP_0002019"},{"id":"A1276","pred":"hp_id","subj":"T1276","obj":"http://purl.obolibrary.org/obo/HP_0000737"},{"id":"A1277","pred":"hp_id","subj":"T1277","obj":"http://purl.obolibrary.org/obo/HP_0002583"},{"id":"A1278","pred":"hp_id","subj":"T1278","obj":"http://purl.obolibrary.org/obo/HP_0001626"}],"text":"In humans, this drug was marketed for women with constipation-predominant or mixed symptom irritable bowel syndrome and demonstrated clear benefits in quality of life and gastrointestinal symptoms but is currently only available in a restricted fashion because of an association with ischemic colitis and cardiovascular disease."}